Sanofi halves US price of Zaltrap, responding to criticism from oncologists
French drug major Sanofi (Euronext: SAN) has said that it would halve the price of its colorectal cancer drug Zaltrap (ziv-aflibercept) in the USA, The Cancer Letter reported last week, saying this was due to criticism from oncologists.
Critics said that Zaltrap’s price - about $11,000 a month - was more than double that of a competing therapy, Roche/Genentech’s Avastin (bevacizumab), which is also used in the second-line colon cancer indication. Sanofi has reportedly set its Zaltrap price at a similar level to Avastin.
Last month, three doctors from Memorial Sloan-Kettering Cancer Center wrote an editorial for The New York Times, explaining their decision to exclude Zaltrap from the cancer center’s formulary.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze